title: Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.
abstract: BACKGROUND
  Sagopilone is the first fully synthetic epothilone in clinical development and has demonstrated promising preclinical activity. This phase I/II, prospective, open-label trial investigated the efficacy and safety of sagopilone plus carboplatin in patients with recurrent platinum-sensitive ovarian cancer (OC).
  
  
  METHODS
  In phase I (dose-escalation stage), patients with OC recurring at least 6 months after platinum-containing chemotherapy received 3-h infusions of sagopilone (initial dose of 12 mg m(-2)) followed by carboplatin every 3 weeks, for 2-6 treatment courses. Patients enrolled in phase II received 3-h infusions of 16 mg m(-2) sagopilone. Efficacy was assessed using modified Response Evaluation Criteria in Solid Tumors (modRECIST) and Gynecologic Cancer InterGroup CA125 criteria. The safety and tolerability of sagopilone were also evaluated.
  
  
  RESULTS
  In all, 45 patients received sagopilone at 12 mg m(-2) or 16 mg m(-2). There were 29 confirmed tumour responses (21 modRECIST and 8 CA125) across both treatment groups, indicating that the primary objective of the study was reached. The main adverse events (AEs) reported were peripheral neuropathy (75.6%), fatigue (71.1%) and nausea (64.4%). Grade ≥3 AEs occurred in 35 patients (77.8%). No deaths related to the study drug were reported.
  
  
  CONCLUSIONS
  Sagopilone in combination with carboplatin was effective and toxicities were manageable in patients with recurrent platinum-sensitive OC.
authors: University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, 825 NE 10th Street, Oklahoma City, OK 73104, USA. scott-mcmeekin@ouhsc.edu
authors: S
authors: S
authors: McMeekin
authors: R
authors: R
authors: Patel
authors: C
authors: C
authors: Verschraegen
authors: P
authors: P
authors: Celano
authors: J
authors: J
authors: Burke
authors: S
authors: S
authors: Plaxe
authors: P
authors: P
authors: Ghatage
authors: M
authors: M
authors: Giurescu
authors: C
authors: C
authors: Stredder
authors: Y
authors: Y
authors: Wang
authors: T
authors: T
authors: Schmelter
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D052160:Benzothiazoles / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D034261:Epothilones / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence
chemical_list: D052160:Benzothiazoles; D034261:Epothilones; D016190:Carboplatin; C530494:sagopilone